# Trial of Screening for ALOA-IgG AtheroAbzyme Test

Study · id `cardio:ct-nct01272986` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01272986](<https://clinicaltrials.gov/study/NCT01272986>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01272986

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01272986. Non-randomized; no masking; primary purpose diagnostic. Start 2011-01 (registry gives no type); primary completion 2011-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01272986, source copy `cardio:ctgov-nct01272986-2011-03-08`, retrieved 2026-10-31)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01272986, source copy `cardio:ctgov-nct01272986-2011-03-08`, retrieved 2026-10-31)
- Primary completion: 2011-03 (actual) (ClinicalTrials.gov record NCT01272986, source copy `cardio:ctgov-nct01272986-2011-03-08`, retrieved 2026-10-31)
- Completion: 2011-03 (actual) (ClinicalTrials.gov record NCT01272986, source copy `cardio:ctgov-nct01272986-2011-03-08`, retrieved 2026-10-31)
- Countries: Lebanon (ClinicalTrials.gov record NCT01272986, source copy `cardio:ctgov-nct01272986-2011-03-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01272986-2011-03-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Trial of Screening for ALOA-IgG AtheroAbzyme Test
- Acronym: OP512011
- Condition: Myocardial Ischemia
- Condition: Acute Coronary Syndrome
- Intervention (Device): ALOA IgG-Elisa
- Intervention (Device): ALOA IgG-AtheroAbzyme
- Lead sponsor: Omicron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Omicron Pharmaceuticals (`cardio:org-omicron-pharmaceuticals`)

## Provenance

Content hash: 0a74486471cf4a94a3570604c1be864c33693fc759abcaa92854eb3edf2e39aa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
